Department of Medicine, University of California San Diego, San Diego, CA, USA.
Department of Medicine, Center for Cardiovascular Research, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
QJM. 2022 Nov 14;115(11):719-725. doi: 10.1093/qjmed/hcab011.
Although it is a member of the Interleukin (IL)-1 family, IL-37 is unique in that it has wide-ranging anti-inflammatory characteristics. It was originally thought to prevent IL-18-mediated inflammation by binding to the IL-18-binding protein. However, upon discovery that it binds to the orphan receptor, IL-1R8, further studies have revealed an expanded role of IL-37 to include several intracellular and extracellular pathways that affect various aspects of inflammation. Its potential role specifically in cardiovascular diseases (CVD) stemmed initially from the discovery of elevated plasma IL-37 levels in human patients with acute coronary syndrome and atrial fibrillation. Other studies using mouse models of ischemia/reperfusion injury, vascular calcification and myocardial infarction have revealed that IL-37 can have a beneficial role in these conditions. This review will explore recent research on the effects of IL-37 on the pathogenesis of CVD.
虽然白细胞介素（IL）-37 是 IL-1 家族的一员，但它具有广泛的抗炎特性，这使其独具特色。最初，人们认为它通过与白细胞介素-18 结合蛋白结合来防止 IL-18 介导的炎症。然而，在发现它与孤儿受体 IL-1R8 结合之后，进一步的研究揭示了 IL-37 的作用扩大到包括几个影响炎症各个方面的细胞内和细胞外途径。它在心血管疾病（CVD）中的特定作用最初源于在患有急性冠状动脉综合征和心房颤动的人类患者的血浆中发现了升高的 IL-37 水平。使用缺血/再灌注损伤、血管钙化和心肌梗死的小鼠模型进行的其他研究表明，IL-37 可以在这些情况下发挥有益作用。这篇综述将探讨最近关于 IL-37 对 CVD 发病机制影响的研究。
